SI2774991T1 - A system for supplying a medicament for use in the treatment or diagnosis of neurological disorders - Google Patents
A system for supplying a medicament for use in the treatment or diagnosis of neurological disorders Download PDFInfo
- Publication number
- SI2774991T1 SI2774991T1 SI201330957T SI201330957T SI2774991T1 SI 2774991 T1 SI2774991 T1 SI 2774991T1 SI 201330957 T SI201330957 T SI 201330957T SI 201330957 T SI201330957 T SI 201330957T SI 2774991 T1 SI2774991 T1 SI 2774991T1
- Authority
- SI
- Slovenia
- Prior art keywords
- vlp
- pain
- use according
- disease
- disorder
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title claims abstract 10
- 238000003745 diagnosis Methods 0.000 title claims abstract 5
- 208000025966 Neurological disease Diseases 0.000 title claims abstract 3
- 238000012377 drug delivery Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 claims abstract 11
- 229940079593 drug Drugs 0.000 claims abstract 7
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract 5
- 208000018737 Parkinson disease Diseases 0.000 claims abstract 4
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 4
- 208000002193 Pain Diseases 0.000 claims 9
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 4
- 206010010904 Convulsion Diseases 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 201000003631 narcolepsy Diseases 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims 4
- -1 thrombolytics Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010054196 Affect lability Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 206010008748 Chorea Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000033001 Complex partial seizures Diseases 0.000 claims 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 2
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims 2
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000026072 Motor neurone disease Diseases 0.000 claims 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 2
- 208000002033 Myoclonus Diseases 0.000 claims 2
- 206010057852 Nicotine dependence Diseases 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 206010039424 Salivary hypersecretion Diseases 0.000 claims 2
- 208000018642 Semantic dementia Diseases 0.000 claims 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 2
- 208000032140 Sleepiness Diseases 0.000 claims 2
- 206010041349 Somnolence Diseases 0.000 claims 2
- 208000005392 Spasm Diseases 0.000 claims 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims 2
- 206010044074 Torticollis Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 201000002866 cervical dystonia Diseases 0.000 claims 2
- 208000012601 choreatic disease Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000001054 cortical effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 206010022437 insomnia Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 208000026451 salivation Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 230000037321 sleepiness Effects 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 201000007905 transthyretin amyloidosis Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- 241000701460 JC polyomavirus Species 0.000 claims 1
- 208000019430 Motor disease Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000012886 Vertigo Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 229940005524 anti-dementia drug Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 208000018300 basal ganglia disease Diseases 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000003825 glutamate receptor antagonist Substances 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 239000004090 neuroprotective agent Substances 0.000 claims 1
- 239000002664 nootropic agent Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000003368 psychostimulant agent Substances 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960000103 thrombolytic agent Drugs 0.000 claims 1
- 230000002537 thrombolytic effect Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 231100000889 vertigo Toxicity 0.000 claims 1
- 241001505332 Polyomavirus sp. Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22041—Use of virus, viral particle or viral elements as a vector
- C12N2710/22042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22041—Use of virus, viral particle or viral elements as a vector
- C12N2710/22043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22071—Demonstrated in vivo effect
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/000656 WO2013131644A1 (en) | 2012-03-06 | 2013-03-06 | A novel drug delivery system based on jcv-vlp |
| EP13001491.3A EP2774991B1 (en) | 2013-03-06 | 2013-03-22 | Drug delivery system for use in the treatment or diagnosis of neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2774991T1 true SI2774991T1 (en) | 2018-04-30 |
Family
ID=47915420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201330957T SI2774991T1 (en) | 2013-03-06 | 2013-03-22 | A system for supplying a medicament for use in the treatment or diagnosis of neurological disorders |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP2774991B1 (enExample) |
| CY (1) | CY1120278T1 (enExample) |
| HR (1) | HRP20180361T1 (enExample) |
| LT (1) | LT2774991T (enExample) |
| NO (1) | NO2774991T3 (enExample) |
| PL (1) | PL2774991T3 (enExample) |
| SI (1) | SI2774991T1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3031821A1 (en) * | 2014-12-08 | 2016-06-15 | Life Science Inkubator | polyomavirus VLPs with a fusion protein |
| EP3031820A1 (en) | 2014-12-08 | 2016-06-15 | Life Science Inkubator | JC Polyomavirus VLP (virus-like particle) with a targeting peptide |
| RU2682966C1 (ru) * | 2018-03-20 | 2019-03-25 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Комбинации буспирона для лечения головокружения |
| CN111323527B (zh) * | 2018-12-13 | 2022-12-02 | 湖南德米特仪器有限公司 | 一种用复合二维液相色谱同时测定多种精神药物的方法 |
| CN112137994B (zh) * | 2020-09-15 | 2022-10-14 | 中山大学 | 小分子化合物在制备抗丝状病毒药物中的应用 |
| CN115317614B (zh) * | 2022-10-14 | 2022-12-27 | 暨南大学 | Adk抑制剂在制备治疗脊髓损伤的药物中的应用 |
| AU2023383549A1 (en) | 2022-11-17 | 2025-06-05 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
| CN117442618B (zh) * | 2023-10-23 | 2025-11-14 | 国科大杭州高等研究院 | 化合物ly2940094在制备治疗中枢神经系统脱髓鞘疾病药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19543553B4 (de) | 1995-11-22 | 2009-04-09 | Deutsches Primatenzentrum Gmbh | VP-Antigene des JC-Virus |
| EP0977596B1 (en) | 1997-04-26 | 2004-01-21 | Rpms Technology Limited | Use of papovavirus capsid protein for delivery of therapeutic agents to neuronal cells |
| DE10131145B4 (de) * | 2001-06-28 | 2005-07-14 | Innovent E.V. | Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen |
| EP2036980A1 (de) | 2007-09-14 | 2009-03-18 | Gruber, Jens | Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel |
| WO2010090757A1 (en) * | 2009-02-05 | 2010-08-12 | Biogen Idec Ma Inc. | Methods for the detection of jc polyoma virus |
-
2013
- 2013-03-22 NO NO13001491A patent/NO2774991T3/no unknown
- 2013-03-22 EP EP13001491.3A patent/EP2774991B1/en active Active
- 2013-03-22 LT LTEP13001491.3T patent/LT2774991T/lt unknown
- 2013-03-22 EP EP17205393.6A patent/EP3312283A1/en not_active Withdrawn
- 2013-03-22 PL PL13001491T patent/PL2774991T3/pl unknown
- 2013-03-22 SI SI201330957T patent/SI2774991T1/en unknown
-
2018
- 2018-02-28 CY CY20181100252T patent/CY1120278T1/el unknown
- 2018-02-28 HR HRP20180361TT patent/HRP20180361T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2774991T3 (pl) | 2018-05-30 |
| LT2774991T (lt) | 2018-03-26 |
| HRP20180361T1 (hr) | 2018-04-20 |
| EP2774991B1 (en) | 2017-12-06 |
| EP3312283A1 (en) | 2018-04-25 |
| EP2774991A1 (en) | 2014-09-10 |
| CY1120278T1 (el) | 2019-07-10 |
| NO2774991T3 (enExample) | 2018-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180361T1 (hr) | Sustav za isporuku lijeka za liječenje ili dijagnozu neuroloških poremećaja | |
| Holm et al. | Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases | |
| JP2025156319A (ja) | 組織特異的なａｐｏｅ調節のためのオリゴヌクレオチド | |
| FI3673080T3 (fi) | Antisense-oligomeerejä häiriötilojen ja sairauksien hoitoon | |
| CA3133784A1 (en) | Oligonucleotide-based modulation of c9orf72 | |
| JP2013135695A5 (enExample) | ||
| JP2019519218A5 (enExample) | ||
| JP2014500249A5 (enExample) | ||
| MX357803B (es) | Moléculas de ácido nucleico artificiales. | |
| CA2980337A1 (en) | Oligonucleotide compounds for targeting huntingtin mrna | |
| SI2823048T1 (en) | A new drug delivery system based on JCV-VLP | |
| JP2014520072A5 (enExample) | ||
| JP2016509061A5 (enExample) | ||
| JP2009525323A5 (enExample) | ||
| US9809823B2 (en) | DNA aptamers for promoting remyelination | |
| JP7660515B2 (ja) | 病態及び疾患の治療用アンチセンスオリゴマー | |
| RU2015155332A (ru) | Олигонуклеотидные модуляторы в-клеточной cll/лимфомы 11а (bcl11а) и их применение | |
| IN2014DN06920A (enExample) | ||
| WO2013173827A3 (en) | Methods and compositions for inhibiting diseases of the central nervous system | |
| JP2012526848A5 (enExample) | ||
| Maxwell | RNAi applications in therapy development for neurodegenerative disease | |
| RU2020114744A (ru) | Способы и композиции для эффективной доставки через множество биобарьеров | |
| WO2009152500A4 (en) | Methods and compositions for mediating gene silencing | |
| Mohanty et al. | Brain targeting of siRNA via intranasal pathway | |
| Moradi et al. | Targeted delivery of therapeutic agents by smart nanocarrier for treatment of Parkinson’s disease: A novel brain targeting approach |